Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

CNS 2Dermatologic 1

Conditions

Neuroblastoma 2Melanoma 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Buthionine Sulfoximine × Clear all
NCT00002730 2024-11-20

Chemotherapy in Treating Children With Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
CNS

Neuroblastoma

NCT00005835 2023-04-10

BSO

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
31 enrolled
CNS

Neuroblastoma

NCT00661336 2015-03-13

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

Duke University

Phase 1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡